Table 5.

Seropositivity of anti–EBV viral capsid antigen immunoglobulin A and anti–EBV DNase at study entry for 31 newly developed cases of nasopharyngeal carcinoma stratified by period after enrollment

Years after enrollmentTotal (n)Anti–EBV VCA IgA
Anti–EBV DNase
Negative [n (%)]Positive [n (%)]Negative [n (%)]Positive [n (%)]
1-553 (60.0)2 (40.0)3 (60.0)2 (40.0)
6-1076 (85.7)1 (14.3)4 (57.1)3 (42.9)
11-15109 (90.0)1 (10.0)9 (90.0)1 (10.0)
>1599 (100.0)0 (0.0)7 (77.8)2 (22.2)
P value based on trend testP = 0.046P = 0.257
  • NOTE: Anti-EBV seromarkers for one nasopharyngeal carcinoma case were not available.